Recent advances in targetable therapeutics in metastatic non-squamous NSCLC

Pranshu Bansal, Diaa Osman, Gregory N. Gan, George R. Simon, Yanis Boumber*

*Corresponding author for this work

Research output: Contribution to journalShort survey

21 Scopus citations

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET, and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding.

Original languageEnglish (US)
Article number112
JournalFrontiers in Oncology
Volume6
Issue numberMAY
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • ALK
  • BRAF
  • C-MET
  • EGFR
  • HER2
  • NSCLC
  • ROS1
  • VEGFR2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recent advances in targetable therapeutics in metastatic non-squamous NSCLC'. Together they form a unique fingerprint.

  • Cite this